Summary One hundred and sixty one children who have developed more than one primary neoplasm have been identified. Children with tumours of the central nervous system, retinoblastoma and leukaemia were those most frequently observed to develop a second malignancy whilst osteosarcoma was the most common second tumour. The patterns of second neoplasms appear to be changing and a recent increase in the number of children with leukaemia and lymphoma who develop second primary tumours has been observed. In this series, the two most frequent associations of tumours were retinoblastoma followed by osteosarcoma and the combination of acute leukaemia with a tumour of the central nervous system. Genetic factors which may have contributed to the development of the second primary tumour were identified in 53 patients (33%), 33 of whom had the genetic form of retinoblastoma. In an analysis of the treatment of 151 patients, for whom the interval between the two neoplasms was greater than 12 months, the second malignancy was considered to be 'radiation associated' in 93 (61%). Fifty children (33%) had been treated with either single or multiple agent chemotherapy which included an alkylating agent in 38. Forty five children had received a combination of chemotherapy and radiotherapy and of these, 10 developed leukaemia as their second tumour. Of the 19 secondary leukaemias, 16 have occurred in patients treated since 1970.
About one in 10,000 children in Britain develop cancer each year (Draper et al., 1982) . At present about 50% of these children can be expected to survive for at least five years which means that there are -600 patients each year who will become 'long term' survivors. A large proportion of these survivors will reach adulthood, potentially 'cured' of their tumours. Recently however, the considerable optimism engendered amongst clinicians by this improvement in survival has been tempered by a growing awareness that patients who have been successfully treated for one cancer appear to be at greater risk than the general population of developing a second histologically distinct malignancy (Li, 1977; Mike et al., 1982; Meadows et al., 1985; Hawkins et al., 1987) . Although the occurrence of multiple primary tumours in any individual may reflect an inherent predisposition to cancer, it is likely that the therapies given to eradicate the first tumour are significant factors in the pathogenesis of many, perhaps most, second primary tumours.
In an attempt to discern possible aetiological factors in the development of multiple primary tumours in childhood cancer patients, a registry has been established to identify those patients treated in Britain who develop second malignancies. The patterns of multiple tumours in these patients are the subject of this study. In this report we describe 161 patients who have developed more than one primary neoplasm and examine the various factors which may have influenced the development of the second primary tumour. We have not attempted to estimate the risk of developing a second tumour in this paper as an analysis of incidence rates is the subject of a separate communication (Hawkins et al., 1987) . Our main purpose here is to describe the patterns of multiple tumours that have been observed and to identify the possible influence of genetic factors and previous therapy in the pathogenesis of the second tumour. Thirteen of the patients included in this series have been described in previous case reports (Anderson & Treip 1983; Judge et al., 1984; Koriech & McNaught, 1981; Lee et al., 1975; Pearson et al., 1983;  *Current address: Department of Paediatric Oncology, St Bartholomew's Hospital, West Smithfield, London ECIA 7BE, UK. Correspondence: J.E. Kingston. Received 5 May 1987. Prentice et al., 1980; Secker-Walker et al., 1985; Stevenson et al., 1981; Ingram et al., 1987) ; a further 24 patients treated in the Manchester region, have been included in a report of second cancers in children from the Late Effects Study Group (LESG) and 34 of the 37 patients with retinoblastoma were included in a paper on second tumours in retinoblastoma by Draper et al. (1986) .
Materials and methods
The criteria for inclusion of a patient in our registry of multiple primary tumour cases were based on the principles of Warren and Gates (1932) as follows: each tumour presented its own distinct histological malignant pattern and the possibility that either tumour was a metastasis was excluded. All patients included in this report had their first cancer diagnosed during the period 1940-1982 and were below the age of 15 years at diagnosis of their first tumour. Patients in whom the second tumour was diagnosed within one year of the first tumour have been defined as 'simultaneous' double tumour cases and have been excluded from the analysis of treatment factors, the rationale for this being that chemotherapy and radiation are unlikely to be significant factors in the pathogenesis of a second tumour occurring within 12 months of treatment of the first. The 'simultaneous' cases have, however, been included in the analysis of genetic factors. Although we know of 12 patients with retinoblastoma who developed ectopic intracranial lesions in the pineal or suprasellar region (Kingston et al., 1985) , in contrast to some series e.g. Abramson et al. (1984) , we have not included them as second tumour cases as in our opinion the intracranial lesion in these cases is not histologically distinct from the primary retinoblastoma. Further details of the ascertainment of cases will be given by Hawkins et al. (1987) .
Ascertainment of cases

Confirmation of diagnosis
Following the initial ascertainment of a possible multiple primary tumour case, the diagnosis of both the first and second tumour was, wherever possible, confirmed by review of the relevant pathological material. For a few children with retinoblastoma and tumours of the central nervous system, no histological material was available and confirmation of the diagnosis was based on review of the radiological and clinical evidence. Following initial confirmation of a double tumour case, details of the date and age of the patient at diagnosis of each tumour, the sites of both tumours and the treatment given for the first tumour were abstracted from hospital and general practitioner's records. Additional information, including the relationship of the second tumour to the radiation field in individuals treated with radiation, the presence of coexistent chronic disease or congenital abnormalities in the patient and details of malignancies in other members of the family, was also collected. Wherever possible this information was supplemented by the personal knowledge of clinicians involved in the care of the patient.
Results
Ten children developed a second tumour within one year of diagnosis of their first tumour and details of these 'simultaneous' double tumour cases are outlined in Table I (Table VI) . Of these, three families had features of the Li Fraumeni syndrome (Li & Fraumeni, 1969) and three children had a sibling with cancer, in two of whom the tumours were concordant (ALL and CNS tumours). Amongst the 45 children with CNS tumours who subsequently developed a second cancer, there were 15 children with a known genetic disease (10 with neurofibromatosis, 3 with Gorlin's syndrome) and one case each of Turcot's syndrome and tuberose sclerosis. In addition there were 4 children who had a first degree relative with cancer (Table VII) .
Treatment factors
The relationship of the second tumour to previous therapy for the 151 non-simultaneous cases is shown in (Table XI) . (1982) , the estimated cumulative risk was 3.3% at 20 years whilst in a study by Li (1977) , the cumulative risk was 12% for 5-24 years from diagnosis. For survivors of Ewing's sarcoma, Strong et al. (1979) suggested that the cumulative risk of radiation related second tumours might be as high as 35% at 10 years. However since the standard error was 15%, these figures are subject to considerable uncertainty. In a study carried out by the CCRG (Hawkins et al., 1987) , about 4% of 3 year survivors of childhood cancer had developed a second primary cancer during the subsequent 20 year period. The patterns of second tumours appear to be changing; before 1970 the two tumour types most frequently associated with the development of a second tumour were genetic retinoblastoma and tumours of the CNS, whereas since 1970, children with leukaemia and lymphoma have been the major group developing second tumours. This may reflect the improvement in survival for children with leukaemia and lymphoma following the introduction of intensive combined modality treatment programmes and also the longer latent interval for the types of second malignancies most commonly seen in children treated for solid tumours.
The association of acute leukaemia with tumours of the central nervous system (12 patients in this series) has also been noted by Meadows et al. (1977) who observed five patients with leukaemia or lymphoma and glioma in an analysis of 102 second malignant neoplasms observed by members of the Late Effects Study Group. Meadows and her colleagues suggested that the association might be part of a new genetic cancer syndrome. Support for this hypothesis comes from a study of 643 children with CNS tumours carried out by Farwell and Flannery, (1984a) who found an excess of haemopoietic-lymphatic cancer in the siblings of the children with tumours of the CNS.
In our series, osteosarcoma and tumours of the CNS were the most frequently observed second malignant neoplasms. Twenty one of the osteosarcomas occurred in children with retinoblastoma. Our findings are similar to those of the Late Effects Study Group , who have also observed a high frequency of osteosarcoma occurring as a second malignancy in their childhood cancer patients. In our series of 45 children with primary tumours of the CNS, 12 (27%) of the second tumours were also in the CNS. Five of the 12 had evidence of Von Recklinghausen's disease. In the LESG series, there were 31 children who had their first primary in the CNS but of these only 4 (13%) developed a second tumour within the CNS. In a review of 670 children with CNS tumours, Farwell and Flannery (1984b) found three children who had developed a second tumour within the CNS; the expected number was 0.16 giving a relative risk of 19.
The main points of difference between the findings of the LESG and those of our study are, firstly, the relative infrequency of children with neuroblastoma developing a second malignancy in our series and, secondly, the relatively larger number of children with CNS tumours and acute leukaemia in our study who have developed second tumours. (Risdall et al., 1979) .
In this series of 151 patients with non-simultaneous tumours, 77 of the 125 children treated with radiation developed their second tumour within or on the edge of the radiation field whilst a further 16 children developed acute leukaemia making a total of 93 (61%) which could be described as 'radiation associated'. Twenty one of these radiation related tumours occurred in children who also had a genetically determined susceptibility. In a report by Li and colleagues (1977) , fifteen of 410 patients surviving for 5 years or more developed a second malignant tumour and all but one of the fifteen second cancers described arose in tissues previously irradiated. In an analysis of the LESG data , 208 (67%) of 308 second or subsequent tumours were classified as radiation associated. The carcinogenic potential of low doses of radiation in the development of tumours such as thyroid, salivary gland and brain tumours has also been stressed (Modan et al., 1974; Curtin et al., 1977) . Twenty five of the second tumours associated with radiation therapy in this series developed on the edge of a radiation field.
The association between retinoblastoma and osteosarcomas occurring either within or outside the radiation field is well recognised (Reese et al., 1949; Abramson et al., 1976) . In addition, there appears to be a specific association between retinoblastoma and other types of sarcoma and possibly also with melanoma (DerKinderen et al., 1986 , 49 (Tucker et al., 1984) . The relative risk of secondary leukaemia was strongly associated with the dose of alkylating agent. Several authors have suggested that the risk of developing a second malignant neoplasm is greatest in patients receiving both chemotherapy and radiotherapy, and there is considerable evidence for this from studies of adult patients (Cadman et al., 1971; Arseneau et al., 1977) . Forty five children (30%), in this series had received both chemotherapy and radiotherapy although in only 35 of these was the radiotherapy thought to have been contributory to the induction of the second tumour.
The occurrence of tumours of the uterus in two patients following oestrogen replacement therapy is of particular interest in view of the occurrence of endometrial cancer following the use of oestrogens in post menopausal women (Jick et al., 1980) . The development of an osteosarcoma in a child with a pituitary adenoma treated with growth hormone is also noteworthy. Meadows and colleagues, (1980) , reported that the development of bone sarcoma occurring as a second neoplasm was significantly influenced by prior radiation therapy and genetic predisposition. In a subsequent analysis of the LESG data, Tucker and colleagues (1985) , showed that exposure to alkylating agents was associated with a significant 2-fold risk of bone cancer and that this was independent of radiation therapy. There is a high incidence of osteosarcoma during adolescence with the peak occurring earlier in girls than in boys, possibly related to the earlier growth spurt in girls. As (Dryja et al., 1986) . Observation of the patterns of double tumours may help direct paths of research in molecular biology and thereby increase our understanding of the molecular mechanisms predisposing to the development of multiple primary tumours.
In conclusion, the number of second primary tumours can be expected to increase as a consequence of the growing numbers of long term survivors of childhood cancer and as the trend for more intensive chemotherapy and combined modality treatments becomes more widely accepted. We predict that this increase will be most pronounced in those childhood cancer survivors with a genetic susceptibility. Therefore it behoves clinicians to identify children with cancer prone conditions so that treatment protocols containing potentially oncogenic therapies such as alkylating agents and irradiation may be reconsidered for such patients. With the introduction of new, effective, non-alkylating cytotoxic agents, it may be possible to eliminate alkylating agents from protocols for patients with a favourable prognosis, thereby reducing the risk of inducing a second tumour without compromising survival. Long term follow up of childhood cancer patients is needed to determine the magnitude of the problem of second primary malignancies and to continue identification of possible aetiological factors.
